Literature DB >> 16725212

IL-6-deficient mice show impaired inflammatory response in a model of myosin-induced experimental myositis.

Flavia Scuderi1, Francesca Mannella, Mariapaola Marino, Carlo Provenzano, Emanuela Bartoccioni.   

Abstract

Inflammatory/immune reactions against muscle cells are responsible for the damage in idiopathic inflammatory myopathies. We investigated the role of IL-6, a cytokine known to contribute to local leukocyte accumulation, in a model of myosin-induced experimental myositis. After injection of rabbit myosin in CFA/pertussis toxin, normal mice develop clinically evident muscle deficit and damage, as demonstrated by myofiber necrosis and leukocyte infiltration, while IL-6-deficient mice have no clinical or histological signs of muscle damage. This study evidences that selective deficiency of IL-6 directly or indirectly hinders the local inflammatory response and its harmful effects in this model of muscle damage.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16725212     DOI: 10.1016/j.jneuroim.2006.03.026

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  10 in total

Review 1.  Animal models of inflammatory myopathy.

Authors:  Dana P Ascherman
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

Review 2.  Pathogenesis, classification and treatment of inflammatory myopathies.

Authors:  Mei Zong; Ingrid E Lundberg
Journal:  Nat Rev Rheumatol       Date:  2011-04-05       Impact factor: 20.543

3.  Impaired muscle strength is associated with ultrastructure damage in myositis.

Authors:  Andrea Aguilar-Vazquez; Efrain Chavarria-Avila; Mario Salazar-Paramo; Juan Armendariz-Borunda; Guillermo Toriz-González; Marcela Rodríguez-Baeza; Ana Sandoval-Rodriguez; Arisbeth Villanueva-Pérez; Marisol Godínez-Rubí; Jose-David Medina-Preciado; Ingrid Lundberg; Yesenia Lozano-Torres; Cynthia-Alejandra Gomez-Rios; Oscar Pizano-Martinez; Erika-Aurora Martinez-Garcia; Beatriz-Teresita Martin-Marquez; Sergio Duran-Barragan; Brenda-Lucia Palacios-Zárate; Arcelia Llamas-Garcia; Livier Gómez-Limón; Monica Vazquez-Del Mercado
Journal:  Sci Rep       Date:  2022-10-21       Impact factor: 4.996

Review 4.  Inhibition of the interleukin-6 signaling pathway: a strategy to induce immune tolerance.

Authors:  Cheng Zhang; Xi Zhang; Xing-Hua Chen
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

5.  Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.

Authors:  Atsushi Ogata; Toshio Tanaka
Journal:  Int J Rheumatol       Date:  2012-01-18

Review 6.  Antibody Therapies in Autoimmune Inflammatory Myopathies: Promising Treatment Options.

Authors:  Rachel Zeng; Stefanie Glaubitz; Jens Schmidt
Journal:  Neurotherapeutics       Date:  2022-04-08       Impact factor: 6.088

7.  Caspase-1-Dependent Pyroptosis Mediates Adjuvant Activity of Platycodin D as an Adjuvant for Intramuscular Vaccines.

Authors:  Liyan Zhu; Ziyi Han; Yanfei He; Hongxiang Sun
Journal:  Cells       Date:  2022-01-01       Impact factor: 6.600

8.  Serum interleukin-6 expression level and its clinical significance in patients with dermatomyositis.

Authors:  Min Yang; Xiaomin Cen; Qibing Xie; Chuan Zuo; Guixiu Shi; Geng Yin
Journal:  Clin Dev Immunol       Date:  2013-09-03

9.  The injury-induced myokine insulin-like 6 is protective in experimental autoimmune myositis.

Authors:  Ling Zeng; Sonomi Maruyama; Kazuto Nakamura; Jennifer L Parker-Duffen; Ibrahim M Adham; Xuemei Zhong; Han-Kyu Lee; Henry Querfurth; Kenneth Walsh
Journal:  Skelet Muscle       Date:  2014-08-04       Impact factor: 4.912

Review 10.  Role of Myokines in Myositis Pathogenesis and Their Potential to be New Therapeutic Targets in Idiopathic Inflammatory Myopathies.

Authors:  Vlad Mageriu; Emilia Manole; Alexandra E Bastian; Florica Staniceanu
Journal:  J Immunol Res       Date:  2020-07-24       Impact factor: 4.818

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.